Literature DB >> 12119461

German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families.

H Rieder1, M Sina-Frey, A Ziegler, S A Hahn, E Przypadlo, R Kress, B Gerdes, M Colombo Benkmann, T Eberl, R Grützmann, M Lörken, J Schmidt, D K Bartsch.   

Abstract

BACKGROUND: The observation of a familial accumulation of ductal pancreatic adenocarcinoma (PC) and the increased risk for PC in certain hereditary tumor syndromes point to a genetic predisposition for PC. In order to evaluate the characteristics of familial PC, a German national case collection for familial pancreas cancer (FaPaCa) was established. PATIENTS AND METHODS: In FaPaCa, families of patients with PC are being collected, who have at least 1 first-degree relative with PC or with malignant melanoma. Histopathologic verification of tumor diagnoses, acquisition of clinical data, and full genetic counselling are prerequisites for the enrollment of PC families in FaPaCa.
RESULTS: So far, 21 families fulfilled the criteria for partaking in FaPaCa. In 11 families, PC represented the sole tumor entity. Additional tumors included malignant melanoma in 5, breast cancer in 3, and prostatic, colon or lung cancer in 2 families. Compared to the preceding generation, a younger age at diagnosis of PC was observed in the offspring of PC patients (offspring median 53 years vs. parents median 75.5 years).
CONCLUSION: The association of PC and breast cancer, and of PC and malignant melanoma suggests predisposing mutations in the BRCA2 or CDKN2A genes in about one third of the FaPaCa families. Mutational analyses in both candidate genes may help to identify individuals who are at an increased risk for developing PC. A shift towards a younger age at diagnosis in our PC families may indicate genetic anticipation and/or changes of patterns of exogenous risk factors. Copyright 2002 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Year:  2002        PMID: 12119461     DOI: 10.1159/000064320

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  9 in total

Review 1.  Total pancreatectomy: indications, operative technique, and postoperative sequelae.

Authors:  David G Heidt; Charles Burant; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

Review 2.  [Familial pancreatic carcinoma].

Authors:  F Ehehalt; R Grützmann
Journal:  Chirurg       Date:  2011-08       Impact factor: 0.955

Review 3.  Pancreatic cancer screening.

Authors:  Eun Ji Shin; Marcia Irene Canto
Journal:  Gastroenterol Clin North Am       Date:  2012-01-05       Impact factor: 3.806

Review 4.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

5.  Low frequency of CHEK2 mutations in familial pancreatic cancer.

Authors:  Detlef K Bartsch; Kristina Krysewski; Mercedes Sina-Frey; Volker Fendrich; Harald Rieder; Peter Langer; Ralf Kress; Margarete Schneider; Stephan A Hahn; Emily P Slater
Journal:  Fam Cancer       Date:  2006-07-20       Impact factor: 2.375

6.  Anticipation in familial pancreatic cancer.

Authors:  C D McFaul; W Greenhalf; J Earl; N Howes; J P Neoptolemos; R Kress; M Sina-Frey; H Rieder; S Hahn; D K Bartsch
Journal:  Gut       Date:  2005-06-21       Impact factor: 23.059

Review 7.  Familial pancreatic cancer and hereditary syndromes: screening strategy for high-risk individuals.

Authors:  Hiroyuki Matsubayashi
Journal:  J Gastroenterol       Date:  2011-08-17       Impact factor: 7.527

8.  Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.

Authors:  Emily P Slater; Peter Langer; Volker Fendrich; Nils Habbe; Brunhilde Chaloupka; Elvira Matthäi; Mercedes Sina; Stephan A Hahn; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

Review 9.  Familial pancreatic cancer.

Authors:  Harald Rieder; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.